Webinar

The field of antibody-drug conjugates (ADCs) has experienced rapid growth in recent years, with applications extending beyond cancer to various non-cancer indications. To date, 17 ADCs have been approved by regulatory agencies worldwide. Driven by the continuous pursuit of new breakthroughs, the industry is now evolving from traditional ADCs to a broader range of bioconjugates (XDCs), which hold extensive potential for addressing more complex diseases. However, the development of XDCs presents numerous challenges.
 
Among these challenges, the intricate modulation of the druggability of XDC drugs stands out as the most critical issue, with the linker playing a pivotal role. In our upcoming webinar, our experts will delve into novel linker technologies which can modulate physicochemical properties of ADCs & XDCs to enhance druggability and accelerate the discovery and development timelines.
 

Key Learning Objectives:

• Landscape of Bioconjugates (XDCs) and linker-payloads market
• Linker types and applications in different XDC modalities
• Introduce a novel connector for more efficient conjugation
• How WuXi XDC’s integrated service platform can shorten the timeline and accelerate ADCs & XDCs discovery and development

Speaker:
Dr. Jingjie Huang
Head of Payload-Linker Discovery Services
WuXi XDC